Co-Diagnostics (CODX) Q2 FY26 earnings call

Co-Diagnostics is transitioning from platform development to commercialization, marked by the significant FDA submission for its upper respiratory multiplex assay and advancing tuberculosis clinical studies in India. Despite limited current revenue and continued operating losses, the company is focused on disciplined expense management and strategic investments in regulatory milestones and platform expansion, including new blood-based assay capabilities and international joint ventures.